Table 3.
Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in Kawasaki disease (KD) with or without coronary artery lesions (CALs)
| Characteristic | KD with CALs (n = 9) |
KD without CALs (n = 31) |
P | |
|---|---|---|---|---|
| Boys/girls, number | 4/5 | 18/13 | 0.000 | |
| Age, months | 27.1 (20.7) | 22.1 (15.6) | 0.001 | |
| Resistin, 102 ng/ml | Acute stage | 0.46 (0.24) | 0.36 (0.26) | 0.268 |
| Afebrile stage | 0.31 (0.20) | 0.22 (0.22) * | 0.266 | |
| Subacute stage | 0.15 (0.08)** ▲ | 0.13 (0.08) ** | 0.663 | |
| S100A12, 102 ng/ml | Acute stage | 5.09 (2.78) | 5.40 (3.42) | 0.804 |
| Afebrile stage | 4.22 (3.29) | 4.02 (3.63) | 0.883 | |
| Subacute stage | 2.52 (3.16) | 2.65 (2.53)** | 0.899 | |
| sRAGE, 102 pg/ml | Acute stage | 2.97(1.99) | 3.01 (1.92) | 0.959 |
| Afebrile stage | 5.93 (3.59)* | 5.70 (2.64)** | 0.833 | |
| Subacute stage | 7.06 (3.88)* | 6.77 (2.86)** | 0.802 | |
Results are mean (SD) unless stated otherwise. *P < 0.05, **P < 0.01 compared with acute stage; ▲P < 0.05 compared with group afebrile stage.